5 results about "Hepatitis b surface antigen" patented technology

The application discloses an LDH-based vaccine adjuvant and a preparation method and application thereof, and belongs to the technical field of aluminum adjuvant preparation of vaccines, and the preparation method comprises the following steps: mixing at least one of soluble magnesium salt, soluble zinc salt, soluble manganese salt and soluble calcium salt with soluble aluminum salt, and then performing a co-precipitation reaction with a sodium hydroxide aqueous solution in a colloid mill device, and performing crystallization to obtain LDH nanosheets; dispersing the LDH nanosheets in a PBS solution, adding a hepatitis B surface antigen molecule drug, uniformly mixing, and then performing centrifugation to obtain the LDH-based vaccine adjuvant. The LDH-based vaccine adjuvant can significantly promote the maturation of DC cells and the activation of T cells, and the total IgG level reflects the overall humoral immune response intensity of the body to vaccines or pathogens; the LDH-based vaccine adjuvant forms a "storage library" at an injection site to store antigens and slowly release the antigens, and the purpose of long-time continuous stimulation of the immune system in the body is achieved.

This invention belongs to the field of affinity membrane and bioseparation technology, and provides a cellulose-based affinity membrane for hepatitis B virus (HBV), its preparation method, and its application. The affinity membrane consists of a base membrane and an affinity ligand immobilized on the base membrane. The base membrane is a carboxylated cellulose filter membrane or a carboxylated modified cellulose filter membrane. The affinity ligand is a biomolecule that specifically recognizes HBV surface antigen. The carboxyl groups of the base membrane and the amino groups of the affinity ligand are linked by amide bonds. Unreacted carboxyl groups on the base membrane are blocked by a blocking reagent. The carboxyl content of the base membrane is 400-1000 μmol / g, the pore size is 400-1000 nm, and the porosity is 30%-60%. The application refers to the use of the above-mentioned affinity membrane in the specific clearance of HBV from HBV-positive plasma. This invention can achieve efficient and specific clearance of HBV from plasma, maximally preserving the activity and function of normal plasma components, and improving the feasibility of industrial application.

The application belongs to the technical field of pharmaceutical chemistry, and discloses a compound for inhibiting hepatitis B surface antigen and application thereof. It is proved through research that the recombinant plasmid S-HiBiT constructed can characterize the expression and secretion of HBs, and can be used for screening the compound for inhibiting HBs, and a cell model for screening anti-HBV drugs targeting HBsAg, i.e. HepG2-PB-S-HiBiT stable expression cell line. It is verified through experiments that the model is particularly suitable for high-throughput screening of compounds. Compound 1 and compound 3 capable of inhibiting HBsAg are found through screening of a compound library by using the model, the drug has the potential to be further developed into a hepatitis B treatment candidate drug, and a new drug is provided for the treatment of hepatitis B.

The present application relates to the technical field of immunological detection, in particular to hepatitis B PreS1 antigen and its preparation method and application. The present application first selects an active PreS1 polypeptide sequence, which is coupled to a hepatitis B surface antigen HBsAg molecule through a crosslinking agent to obtain a hepatitis B PreS1 antigen having both hepatitis B surface antigen activity and PreS1 antigen activity, which can be used as a calibrator and positive control in a hepatitis B PreS1 antigen detection kit. The kit uses anti-PreS1 antibody as coating and anti-HBsAg antibody as enzyme label. The artificial coupled hepatitis B PreS1 antigen prepared by the present application can effectively replace the currently used PreS1 real positive sample on the market, has no biological safety risk, stable source, and various indexes such as reactivity, vehicle stability and thermal stability, which are all better than those of the real positive sample, and has high innovation and applicability.

This invention discloses a non-invasive systemic assessment method and system for predicting the transformation of follicular lymphoma. The method includes the following steps: S1, obtaining four characteristics of the subject: peripheral blood hepatitis B surface antigen (HBsAg), neutrophil-to-lymphocyte ratio (NLR), serum lactate dehydrogenase (LDH), and PET-CT reporting maximum standardized uptake (SUVmax); S2, determining the weight of each characteristic based on its importance, with the weights from high to low being HBsAg, LDH, NLR, and SUVmax, and converting each characteristic into a risk score of 0-3 points using a unique fixed node; S3, weighted summing of the scores of the four characteristics to obtain a total score S, establishing a correspondence between the total score and transformation, constructing a web-based calculator and transformation scoring system, and outputting the individual transformation probability prediction result. By embedding the four conventional indicators (HBsAg, NLR, LDH, and SUVmax) selected by LASSO and Boruta into a lightweight CatBoost model, the transformation probability can be output, realizing a non-invasive assessment of the histological transformation risk of follicular lymphoma at initial diagnosis.